A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Transplantation

• Publication date

  1991-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00007890-199101000-00016PMID 1846250
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.

  1990cited by this paper
• Cardiac allograft survival in mice treated with IL-2-PE40.

  1989cited by this paper
• Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody.

  1989cited by this paper
• Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody.

  1989cited by this paper
• A humanized antibody that binds to the interleukin 2 receptor.

  1989cited by this paper
• PROLONGATION OF CARDIAC ALLOGRAFT SURVIVAL IN MURINE RECIPIENTS TREATED WITH A DIPHTHERIA TOXIN RELATED INTERLEUKIN‐2 FUSION PROTEIN

  1989cited by this paper
• Early experience with anti-Tac in clinical renal transplantation.

  1989cited by this paper
• Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy.

  1988cited by this paper
• Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.

  1987cited by this paper
• Prolongation of murine cardiac allograft survival by the anti-interleukin-2 receptor monoclonal antibody AMT-13.

  1987cited by this paper
• Interleukin 2 high-affinity receptor expression requires two distinct binding proteins

  1987cited by this paper
• The interleukin 2 receptor. Functional consequences of its bimolecular structure

  1987cited by this paper
• Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.

  1986cited by this paper
• Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.

  1986cited by this paper
• Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression.

  1986cited by this paper
• Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions.

  1986cited by this paper
• The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes.

  1986cited by this paper
• Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice

  1985cited by this paper
• Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen

  1984cited by this paper
• A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

  1981cited by this paper
• T cell growth factor receptors. Quantitation, specificity, and biological relevance

  1981cited by this paper
• A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells.

  1981cited by this paper

• Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins

  2020cites this paper
• Basiliximab (Simulect®) and Daclizumab (Zenapax®)

  2014cites this paper
• Treatment of Autoimmune Disease: Biological and Molecular Therapies

  2014cites this paper
• Risk of serious opportunistic infections after solid organ transplantation: interleukin-2 receptor antagonists versus polyclonal antibodies. A meta-analysis

  2014cites this paper
• Outcomes of living donor renal transplant recipients with and without basiliximab induction: A long-term follow-up study

  2014cites this paper
• Induction Therapy: A Modern Review of Kidney Transplantation Agents

  2013cites this paper
• Monoclonal Antibodies (mAb) in the Therapy of T-Cell Lymphomas

  2013cites this paper
• PRODUCTION AND CHARACTERISATION OF SPECIFIC ANTIBODIES TO BOVINE INTERLEUKIN 5 AND 6 AND THEIR USE IN THE DEVELOPMENT OF SENSITIVE ELISA FOR THEIR MEASUREMENT

  2013cites this paper
• 抗CD25モノクローナル抗体daclizumab（ゼナパックス®）, basiliximab（シムレクト®）

  2013cites this paper
• Role of Anti— Interleukin-2 Receptor Antibodies in Kidney Transplantation

  2012cites this paper
• Islet Transplantation in Patients with Diabetes Mellitus

  2012cites this paper
• Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis

  2012cites this paper
• Newer Immunosuppressive Drugs

  2012cites this paper
• 17 Induction Therapy in Renal Transplant Recipients

  2012cites this paper
• Daclizumab

  2012cites this paper
• Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.

  2012cites this paper
• Induction Therapy in Renal Transplant Recipients

  2012cites this paper
• Biological Agents in Kidney Transplantation

  2010cites this paper
• Interleukin 2 receptor antagonists for kidney transplant recipients.

  2010cites this paper
• Antibody immunosuppressive therapy in solid-organ transplant: Part I.

  2010cites this paper
• Antibody immunosuppressive therapy in solid-organ transplant

  2010cites this paper
• Antibody immunosuppressive therapy in solid organ transplant

  2010cites this paper
• Uric Acid as a Growth Factor for Activated B Cells

  2009cites this paper
• Development and Clinical Application of Double Antibody Sandwich ELISA for WuTac Concentration in Serum

  2009cites this paper
• Forty years of publication of transplantation proceedings-the third decade: the expansion of the enterprise.

  2009cites this paper
• The cost-effectiveness of induction immunosuppression in kidney transplantation.

  2009cites this paper
• New Approaches to Antibody Therapy

  2008cites this paper
• Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference?

  2008cites this paper
• Cytokines: Regulators of Immune Responses and Key Therapeutic Targets

  2008cites this paper
• Chapter 20 – Antibodies and Fusion Proteins

  2008cites this paper
• Daclizumab

  2007cites this paper
• 2006 Homer W. Smith Lecture: taming T cells.

  2007cites this paper
• Anti-Tac (daclizumab, Zenapax) in the Treatment of Leukemia, Autoimmune Diseases, and in the Prevention of Allograft Rejection: A 25-Year Personal Odyssey

  2007cites this paper
• Pharmacologic approaches to composite tissue allograft.

  2007cites this paper
• Humanized Anti-CD25 Antibody Treatment with Daclizumab in Multiple Sclerosis

  2007cites this paper
• The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

  2006cites this paper
• Emerging Therapies for Autoimmune Diseases

  2006cites this paper
• Biologics in the prevention and treatment of graft rejection

  2006cites this paper
• Induction Immunosuppression

  2006cites this paper
• MONOCLONAL ANTIBODIES AS TARGETING AND THERAPEUTIC AGENTS: PROSPECTS FOR LIVER TRANSPLANTATION, HEPATITIS AND HEPATOCELLULAR CARCINOMA

  2006cites this paper
• Signaling T‐Cell Survival and Death by IL‐2 and IL‐15

  2005cites this paper
• Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients.

  2005cites this paper
• Monoclonal antibody-based strategies in autoimmunity and transplantation.

  2005cites this paper
• Immunosuppression for pancreas transplantation

  2005cites this paper
• Daclizumab: humanized monoclonal antibody to the interleukin-2 receptor

  2005cites this paper
• Principles of transplantation immunology

  2005cites this paper
• [Advances in immunossuppression in liver transplantation].

  2005cites this paper
• Immunosuppression in pediatric liver and intestinal transplantation: a closer look at the arsenal.

  2005influential citation
• Avances en inmunosupresión en trasplante hepático

  2005cites this paper
• Future of monoclonal antibodies in solid organ transplantation

  2005cites this paper
• Interleukin 2 receptor antagonists for kidney transplant recipients.

  2004cites this paper
• Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials1

  2004influential citation
• Anesthesia for liver transplant surgery.

  2004cites this paper
• Antibodies in the prevention of renal allograft rejection

  2004cites this paper
• NEPHROLOGY Rounds AS PRESENTED IN THE ROUNDS OF

  2004cites this paper
• Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants.

  2004cites this paper
• Simulect induction facilitates Neoral-based steroid-free immunosuppression in primary kidney transplant recipients.

  2004cites this paper
• Immunosuppression for Cardiac Transplantation

  2004cites this paper
• The Interleukin-2 Receptor : A Target for Monoclonal Antibody Treatment of Human Tc e l l Lymphotrophic Virus I-Induced Adult Tc e l l Leukemia

  2003cites this paper
• Adoptive Immunotherapy

  2003cites this paper
• Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.

  2003cites this paper
• Basiliximab: efficacy and tolerability in adults and children.

  2003cites this paper
• Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

  2003cites this paper
• Liver failure, transplantation, and critical care.

  2003cites this paper
• lnterleukin-2 receptor antibodies for cardiac allograft

  2002cites this paper
• The Interleukin 2 “Pathway” and the Route to Logical Immunosuppression

  2002cites this paper
• Effect of Anti‐IL‐2Rα Antibody on IL‐2‐induced Jak/STAT Signaling

  2002cites this paper
• Limited Dose Monoclonal IL‐2R Antibody Induction Protocol after Primary Kidney Transplantation

  2002cites this paper
• Immunosuppressive Therapy in Solid Organ Transplantation

  2002cites this paper
• Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.

  2002cites this paper
• CHAPTER 8 Interleukin-2 receptor antibodies for cardiac allograft

  2002cites this paper
• Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction.

  2002cites this paper
• The utility of monoclonal antibody therapy in renal transplantation.

  2002cites this paper
• Targeting the IL-2 receptor with antibodies or chimeric toxins

  2001cites this paper
• New Immunosuppressive Agents

  2001cites this paper
• Monoclonal Antibody Targeting of the Il-2R Complex

  2001cites this paper
• Induction therapy with daclizumab as part of the immunosuppressive regimen in human small bowel and multiorgan transplants.

  2001cites this paper
• Nuevos tratamientos inmunodepresores de inducción en el trasplante renal

  2001cites this paper
• Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL‐2 receptor (DACLIZUMAB) on collagen‐induced arthritis (CIA) in rhesus monkeys

  2001cites this paper
• [New induction immunosuppression treatments in kidney transplantation].

  2001cites this paper
• Polyclonal and Monoclonal Antibodies

  2001cites this paper
• Clinical Trials in Transplant Immunosuppression: What Have We Learned?

  2001cites this paper
• Immunomodulatory Function of MHC Peptides

  2001cites this paper
• Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis

  2000cites this paper
• New trends in immunosuppression.

  2000cites this paper
• Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients.

  2000cites this paper
• Current treatment practice in immunosuppression

  2000cites this paper
• Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids.

  2000cites this paper
• The Potential of Newer Immunomodulating Drugs in the Treatment of Uveitis

  2000cites this paper
• Mechanisms of Action of Immunosuppressants and Immunoinductors

  2000cites this paper
• Novel therapeutic approaches to Guillain-Barré syndrome

  2000cites this paper
• Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and

  2000cites this paper
• [Immunosuppression after renal transplantation].

  2000cites this paper
• Promising New Agents in the Prevention of Transplant Rejection

  1999cites this paper
• IMMUNOSUPPRESSIVE THERAPY: New Concepts

  1999cites this paper
• Anti-CD25 therapy reveals the redundancy of the intragraft cytokine network after clinical heart transplantation.

  1999cites this paper
• Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.

  1999cites this paper
• Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation.

  1999cites this paper
• Mechanisms of induction of renal allograft tolerance in CD45RB-treated mice.

  1999cites this paper
• Newer immunosuppressive drugs: a review.

  1999cites this paper